Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04036877 · ClinicalTrials.gov registry record
Mood Disorders Bladder Cancer
A clinical trial, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- 358
- Enrollment target
NCT04036877: Completed study, sponsored by University of Kansas Medical Center.
NCT04036877 is a clinical trial that has completed, run by University of Kansas Medical Center. The registered enrollment target is 358 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04036877 has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- 358 participants
- Enrollment target
Study Summary
This is a cross-sectional study evaluating mood disorders in bladder cancer patients and their caregivers across the bladder cancer trajectory
Primary Outcome
Assessed using Patient-Health Questionnaire-9. A standard questionnaire with 9 questions. Score 5-9 is minimal symptoms, 10-14 is minor depression, 15-19 is major depression moderately severe, and 20-27 is severe major depression.
Interventions
- OTHER Mood Disorder Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2019-09-19 |
| Est. Completion | 2021-08-04 |
What the finished NCT04036877 record still lists
NCT04036877 is an observational study that tracks outcomes without assigning an intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Mood Disorder Assessment is the first listed.
NCT04036877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04036877 about?
NCT04036877 is a clinical study titled "Mood Disorders Bladder Cancer". This is a cross-sectional study evaluating mood disorders in bladder cancer patients and their caregivers across the bladder cancer trajectory
What is the current status of trial NCT04036877?
This trial is currently completed. The enrollment target is 358 participants. The study started on 2019-09-19. Estimated completion is 2021-08-04.
What interventions are being tested in trial NCT04036877?
The interventions under investigation include: Mood Disorder Assessment (OTHER).
Who is sponsoring clinical trial NCT04036877?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373317 · 358 participants · Phase 4
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- NCT05684965 · 358 participants · Phase 1
XTX301 in Patients With Advanced Solid Tumors
- NCT05824975 · 358 participants · Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- NCT06480227 · 358 participants · NA
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI